ArticleThoracic cancer2018
Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Metastasectomy versus stereotactic body radiotherapy for lung metastases: a systematic review and meta-analysis of reconstructed time-to-event data on overall and progression-free survival.Journal of thoracic disease · 2026Article
- Long-Term Results of Multiple Pulmonary Metastasectomies.Annals of surgical oncology · 2026Article
- Stereotactic Body Radiotherapy vs. Metastasectomy for Soft Tissue and Bone Sarcoma Lung Metastases - A Systematic Review analyzing Safety and Efficacy.Clinical and translational radiation oncology · 2026Review
- Efficacy of Radiotherapy for Oligometastatic Lung Cancer and Irradiation Methods Based on Metastatic Site.Cancers · 2025Review
- Low-Burden Oligometastatic Disease of the Lung Treated with Robotic Stereotactic Ablative Radiotherapy: A Retrospective Study.Biomedicines · 2025Article
- Stereotactic ablative radiotherapy for pulmonary metastasis from sarcoma: a retrospective comparison with metastasectomy.Clinical & experimental metastasis · 2024Article
- Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs.Precision radiation oncology · 2024Review
- Colorectal Pulmonary Metastases: Pulmonary Metastasectomy or Stereotactic Radiotherapy?Cancers · 2023Article
- Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis.Journal of radiation research · 2022Article
- Outcome of lung oligometastatic patients treated with stereotactic body irradiation.Frontiers in oncology · 2022Article
- Impact of tumor size and location on lung dose difference between stereotactic body radiation therapy techniques for non-small cell lung cancer.Thoracic cancer · 2021Article
- Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review.Cancers · 2021Review
- Influence of tumor characteristics on correction differences between cone-beam computed tomography-guided patient setup strategies in stereotactic body radiation therapy for lung cancer.Thoracic cancer · 2020Article
- Correspondence to the editorials on "Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases".Journal of thoracic disease · 2019Article
- The Past, Present and Future of Pulmonary Metastasectomy: A Review Article.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2019Review
- Stereotactic ablative radiotherapy versus metastasectomy for pulmonary metastases: guiding treatment in the oligometastatic era.Journal of thoracic disease · 2019Article
- Stereotactic body radiotherapy as an alternative to metastasectomy for pulmonary oligometastasis.Journal of thoracic disease · 2019Article
- Stereotactic body radiation therapy versus metastasectomy for oligometastases.Journal of thoracic disease · 2019Article
- Comparison of pulmonary metastasectomy and stereotactic body radiation therapy for the treatment of lung metastases.Journal of thoracic disease · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe compared the treatment outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy in patients with pulmonary metastases.
methodsTwenty-one patients received SBRT (total radiation doses 60 Gy in 3 fractions or 48 Gy in 4 fractions) and 30 underwent metastasectomy, most (93.3%) with wedge resection. The patients were followed for a median of 13.7 months. The tumor size in the SBRT group was larger than in the metastasectomy group (median 2.5 vs. 1.25 cm; P = 0.015). Patients with synchronous metastases were more likely to be treated with SBRT than with metastasectomy (P = 0.006).
resultsThere was no significant difference in the local control rates of the treatment groups (P = 0.163). Progression-free survival (PFS) was longer in the metastasectomy than in the SBRT group (P = 0.02), with one and two-year PFS rates of 51.1% and 46% versus 23.8% and 11.9%, respectively. The one and two-year overall survival (OS) rates were 95% and 81.8% in the metastasectomy group and 79.5% and 68.2%, in the SBRT group, respectively. In multivariate analysis, synchronous metastasis was related to poor PFS, and tumor size was the most significant factor affecting OS. There were no significant differences in PFS and OS between treatment groups after dividing patients according to the presence or absence of synchronous metastases.
conclusionsSBRT is considered a suitable local modality against pulmonary metastases; however, patients with synchronous metastases are only likely to obtain a small benefit from local treatment with either SBRT or surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.